Now showing items 1-3 of 3
Long-Term Safety and Efficacy of Abatacept in Children With Juvenile Idiopathic Arthritis
(Arthritis and Rheumatism, 2010-06-01) [Artigo]
Objective. We previously documented that abatacept was effective and safe in patients with juvenile idiopathic arthritis (JIA) who had not previously achieved a satisfactory clinical response with disease-modifying ...
Cumulative long-term safety, efficacy and patient-reported outcomes in children with juvenile idiopathic arthritis treated with intravenous abatacept: up to 7 years of treatment
(Arthritis &rheumatology, 2014-03-01) [Resumo]
The long-term efficacy and safety of intravenous abatacept in patients (pts) with juvenile idiopathic arthritis (JIA) have been reported previously from the Phase III AWAKEN trial ([1, 2]). Here, we report efficacy, safety ...